COGNITIVE FUNCTIONS IN PATIENTS WITH CHRONIC MIGRAINE
Keywords:
migraine, headache, decreased ability to work, quality of life, memory loss, dementia, magnetic resonance imaging, damage to the white and gray matter of the brain.Abstract
Migraine is the second most common form of headache, which affects 11-15% of the adult population [1, 2]. The prevalence of migraine in the adult population in Europe is 14% [3], in China – 9.3% [4], in the USA – 20.2% [5], in Russia – 20.3% [6]. Migraine is one of the most common forms of headache in Uzbekistan. According to research, about 8.1% of the population suffers from migraines, and most often this disease occurs in people aged 30 to 49 years. Women suffer from migraines 2-3 times more often than men. Migraine significantly reduces the ability to work and the quality of life of patients [7]. It was noted that patients with migraine are significantly more likely than in the general population to complain of memory loss [8]. Many researchers point out objective deterioration of cognitive functions in patients with migraine. Other authors, on the contrary, report the absence of objective cognitive impairment in migraines. At the same time, over the past decade, clinical data have been obtained that patients with migraine have an increased risk of stroke, arterial hypertension and diabetes mellitus are more common [9-10]. Interestingly, migraines, as well as ischemic stroke and dementia, are more common in women. In some patients with migraine, magnetic resonance imaging (MRI) reveals areas of damage to the white and, to a lesser extent, gray matter of the brain. The clinical significance of these injuries is debated, and their effect on cognitive functions is unclear.
References
Stovner LJ, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia. 2017 Mar;27(3): 193-210.
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries: a systematic analysis for the Global Burden of Disease Study 2020. Lancet. 2012 Dec 15; 380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2.
Stovner LJ, Zwart JA, Hagen K, et al. Epidemiology of headache in Europe. Eur J Neurol. 2006 Apr;13(4):333-45.
Yu S, Liu R, Zhao G, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2022 Apr;52(4):582-91.
Burch RC, Loder S, Loder E, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015 Jan;55(1):21-34. doi: 10.1111/head.12482.
Ayzenberg I, Katsarava Z, Sborowski A, et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2022 Apr;32(5):373-81. doi: 10.1177/0333102412438977. Epub 2012 Mar 6.
Foti M, Lo Buono V, Corallo F, et al. Neuropsychological assessment in migraine patients: a descriptive review on cognitive implications. Neurol Sci. 2017 Apr;38(4):553-562. doi: 10.1007/s10072-017-2814-z. Epub 2017 Jan 18.
De Araujo CM, Barbosa IG, Lemos SMA, et al. Cognitive impairment in migraine: A systematic review. Dement Neuropsychol. 2022 Apr-Jun;6(2):74-79. doi: 10.1590/S1980- 57642012DN06020002.
Kurth T, Gaziano JM, Cook NR, et al. Migraine and risk of cardiovascular disease in women. JAMA. 2016 Jul 19;296(3):283-91.
Kurth T, Kase CS, Schurks M, et al. Migraine and risk of haemorrhagic stroke in women: prospective cohort study. BMJ. 2020 Aug 24;341:c3659. doi: 10.1136/bmj.c3659.
Kamalova N.L. BOTULINUM THERAPY IN THE TREATMENT OF CHRONIC MIGRAINE. http://www.eijmr.org/index.php/eijmr/article/view/499